Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Biological variation of insulin resistance, testosterone and cardiovascular risk factors in women with polycystic ovarian syndrome: modification with rimonabant [20 mg/day] compared to metformin [1500 mg/day].

Trial Profile

Biological variation of insulin resistance, testosterone and cardiovascular risk factors in women with polycystic ovarian syndrome: modification with rimonabant [20 mg/day] compared to metformin [1500 mg/day].

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2012

At a glance

  • Drugs Rimonabant (Primary) ; Metformin
  • Indications Metabolic syndrome; Obesity; Polycystic ovary syndrome
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Jun 2008 Status changed to completed based on the presentation of primary endpoint data at the 68th Annual Scientific Sessions of the American Diabetes Association.
    • 06 Jun 2008 Results presented at the 68th Annual Scientific Sessions of the American Diabetes Association.
    • 09 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top